Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
「Stock Market Oracle」 Serenity Reviews RPI's Singularity Event: Stock Price Surges 247% Post AI Long Position as Performance Beats Expectations

「Stock Market Oracle」 Serenity Reviews RPI's Singularity Event: Stock Price Surges 247% Post AI Long Position as Performance Beats Expectations

BlockBeatsBlockBeats2026/06/05 09:23

BlockBeats News, June 5th, the "Stock God" Serenity posted stating that, looking back at its investment case for RPI, since releasing its investment thesis, RPI's stock price has risen from 283 British pence (GBX, the UK stock market quoting unit) to 983 British pence, representing a cumulative increase of 247%.


Serenity pointed out that the company's latest disclosed performance guidance indicates that driven by the strong growth in artificial intelligence-related demand, core profits are expected to significantly exceed the market's expectations. Although in February of this year, European media described RPI as a "meme stock" lacking fundamental support, the fact is that the company's stock price increase is not merely based on market sentiment but is built on AI-driven revenue growth and performance improvement.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage